ArticleEuropean child & adolescent psychiatry2011
Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders.
Article in European child & adolescent psychiatry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Safety of aripiprazole for tics in children and adolescents: A systematic review and meta-analysis.Medicine · 2019Pooled it
- Harms of Antipsychotics in Children and Young Adults: A Systematic Review Update.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2018Pooled it
- Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis.CNS drugs · 2016Pooled it
- Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis.BMC psychiatry · 2015Pooled it
- Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and Adolescents.Journal of child and adolescent psychopharmacology · 2017Trial
- Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial.Child psychiatry and human development · 2014Trial
- Randomized, double-blind, placebo-controlled trial of aripiprazole oral solution in children and adolescents with Tourette's disorder.Child and adolescent psychiatry and mental health · 2024Article
- Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2021Article
- The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites.Drug metabolism and disposition: the biological fate of chemicals · 2020Article
- A Review of the Current Treatment of Tourette Syndrome.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2020Review
- Korean Medication Algorithm for Depressive Disorders 2017: Third Revision.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2018Article
- Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders.Pediatric health, medicine and therapeutics · 2016Review
- Twice-weekly aripiprazole for treating children and adolescents with tic disorder, a randomized controlled clinical trial.Annals of general psychiatry · 2016Article
- Perceptions of treatment for tics among young people with Tourette syndrome and their parents: a mixed methods study.BMC psychiatry · 2015Article
- Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.Journal of psychopharmacology (Oxford, England) · 2014Article
- Psychopharmacological treatment in children: always keeping an eye on adherence and ethics.European child & adolescent psychiatry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to its unique pharmacodynamic properties of dopamine partial agonist activity, and its association with few and mild side effects, aripiprazole is a candidate atypical antipsychotic for patients with tic disorders. This open-label study compared the efficacy and tolerability of aripiprazole with haloperidol, a typical antipsychotic widely used to treat patients with tic disorders. Forty-eight children and adolescents with tic disorders were recruited from the outpatient clinic at South Korea and treated with aripiprazole (initial dose, 5.0 mg/d; maximum dose 20 mg/d) or haloperidol (initial dose, 0.75 mg/d; maximum dose, 4.5 mg/d) for 8 weeks. Treatment efficacy was measured using the yale global tic severity scale (YGTSS), and tolerability was measured using the extrapyramidal symptom rating scale (ESRS) and an adverse effects checklist. Total tic scores as measured by the YGTSS decreased over time in both groups (p < 0.001) without any significant differences between groups. ESRS scores were significantly higher in the haloperidol group during the 4 weeks after commencement of medication (p < 0.05). These results indicate that aripiprazole may be a promising drug in the treatment of children and adolescents with tic disorders. Further controlled studies are needed to determine the efficacy and tolerability of aripiprazole in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.